Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulmonx Corp (NQ: LUNG )

11.79 +0.02 (+0.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulmonx Corp

Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Participate at Upcoming Investor Conferences
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx Reports Record Third Quarter 2023 Financial Results
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Participate at Upcoming Investor Conferences
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx Reports Second Quarter 2023 Financial Results
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx Reports First Quarter 2023 Financial Results
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023
From Pulmonx Corporation
Via Business Wire
Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Present at the Citi 2023 Healthcare Conference
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
From Pulmonx Corporation
Via GlobeNewswire
American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema
From Pulmonx Corporation
Via Business Wire
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
From Pulmonx Corporation
Via Business Wire
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Participate at Upcoming Investor Conferences
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx Reports Third Quarter 2022 Financial Results
From Pulmonx Corporation
Via GlobeNewswire
Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022
From Pulmonx Corporation
Via GlobeNewswire
ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
From Pulmonx Corporation
Via Business Wire
Pulmonx to Present at Upcoming September Investor Conferences
From Pulmonx Corporation
Via Business Wire
Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Pulmonx Corporation
Via Business Wire
Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
From Pulmonx Corporation
Via Business Wire
Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment
From Pulmonx Corporation
Via Business Wire
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
From Pulmonx Corporation
Via Business Wire
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
From Pulmonx Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.